These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 38656354)

  • 1. A new vision of the efficacy of both CAR-NK and CAR-T cells in treating cancers and autoimmune diseases.
    Hassan SH; Alshahrani MY; Saleh RO; Mohammed BA; Kumar A; Almalki SG; Alkhafaji AT; Ghildiyal P; Al-Tameemi AR; Elawady A
    Med Oncol; 2024 Apr; 41(6):127. PubMed ID: 38656354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
    Rafei H; Daher M; Rezvani K
    Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR-NK cells: A promising cellular immunotherapy for cancer.
    Xie G; Dong H; Liang Y; Ham JD; Rizwan R; Chen J
    EBioMedicine; 2020 Sep; 59():102975. PubMed ID: 32853984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges.
    Kong JC; Sa'ad MA; Vijayan HM; Ravichandran M; Balakrishnan V; Tham SK; Tye GJ
    Front Immunol; 2024; 15():1384039. PubMed ID: 38726000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.
    Bachiller M; Perez-Amill L; Battram AM; Carné SC; Najjar A; Verhoeyen E; Juan M; Urbano-Ispizua A; Martin-Antonio B
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34433634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells.
    Herrera L; Santos S; Vesga MA; Anguita J; Martin-Ruiz I; Carrascosa T; Juan M; Eguizabal C
    Sci Rep; 2019 Dec; 9(1):18729. PubMed ID: 31822751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
    Mehta RS; Rezvani K
    Front Immunol; 2018; 9():283. PubMed ID: 29497427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A structural, genetic and clinical comparison of CAR-T cells and CAR-NK cells: companions or competitors?
    Andrea AE; Chiron A; Sarrabayrouse G; Bessoles S; Hacein-Bey-Abina S
    Front Immunol; 2024; 15():1459818. PubMed ID: 39430751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
    Nguyen S; Lacan C; Roos-Weil D
    Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.
    Morandi F; Yazdanifar M; Cocco C; Bertaina A; Airoldi I
    Cells; 2020 Jul; 9(8):. PubMed ID: 32707982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.
    Yilmaz A; Cui H; Caligiuri MA; Yu J
    J Hematol Oncol; 2020 Dec; 13(1):168. PubMed ID: 33287875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review.
    Dash CP; Sonowal D; Dhaka P; Yadav R; Chettri D; Satapathy BP; Sheoran P; Uttam V; Jain M; Jain A
    Front Immunol; 2024; 15():1390498. PubMed ID: 38694508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages.
    Ebrahimiyan H; Tamimi A; Shokoohian B; Minaei N; Memarnejadian A; Hossein-Khannazer N; Hassan M; Vosough M
    Int Immunopharmacol; 2022 May; 106():108587. PubMed ID: 35149294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
    Wang W; Jiang J; Wu C
    Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR-NK Cell Therapy: A Transformative Approach to Overcoming Oncological Challenges.
    Li W; Wang X; Zhang X; Aziz AUR; Wang D
    Biomolecules; 2024 Aug; 14(8):. PubMed ID: 39199421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cell-related anti-tumour adoptive cell immunotherapy.
    Qi Y; Li Y; Wang H; Wang A; Liu X; Liang Z; Gao Y; Wei L
    J Cell Mol Med; 2024 Jun; 28(11):e18362. PubMed ID: 38837666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in CAR-NK cell therapy for hematological malignancies.
    Yang R; Yang Y; Liu R; Wang Y; Yang R; He A
    Front Immunol; 2024; 15():1414264. PubMed ID: 39007146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR-expressing NK cells for cancer therapy: a new hope.
    Xia J; Minamino S; Kuwabara K
    Biosci Trends; 2020 Nov; 14(5):354-359. PubMed ID: 32893255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.